{"schema_version":"secwatch.filing_event.v1","accession":"0000950170-24-002738","form_type":"8-K","ticker":"STAA","cik":"0000718937","company_name":"STAAR SURGICAL CO","filed_at":"2024-01-08T23:59:59+00:00","discovered_at":"2026-05-14T18:03:26.741596+00:00","generated_at":"2026-06-07T02:41:53.434556+00:00","sec_items":["2.02","7.01","9.01"],"event_type":"earnings","sentiment":"positive","materiality_score":0.7,"calibrated_materiality_score":0.7,"confidence":"high","headline":"STAAR Surgical prelim Q4 net sales ~$76.5M, ICL sales +22%; FY2024 outlook $335-340M","bullets":["Preliminary FY2023 net sales ~$322.5M (+13% YoY); Q4 net sales ~$76.5M (+19% YoY).","Global ICL sales up 22% in Q4 (APAC +26%) and 18% for FY2023; ICL unit growth outpaced refractive industry by 26 points in 2023.","FY2024 net sales guidance of $335-340M, implying ~10% ICL growth in both China and U.S.; GAAP operating margin expected at least breakeven.","Cash and investments ~$230M, up ~$28M from Q3; accounts receivable ~$90M.","Full FY2023 results to be reported on or about Feb 21, 2024."],"urls":{"canonical":"https://secwatch.observer/filing/0000950170-24-002738","json":"https://secwatch.observer/filing/0000950170-24-002738.json","markdown":"https://secwatch.observer/filing/0000950170-24-002738.md","text":"https://secwatch.observer/filing/0000950170-24-002738.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/718937/000095017024002738/0000950170-24-002738-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/718937/000095017024002738/staa-20240108.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-07T02:41:53.434556+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"332ee6b908e44803950cf1d089910a81c41277c6","claim":"STAAR SURGICAL CO reported fiscal year ended December 29, 2023 results: revenue Net sales of approximately $322.5 million for fiscal 2023 (preliminary). Guidance initiated.","evidence_excerpt":"STAAR Surgical Company (NASDAQ: STAA), a leading developer, manufacturer and marketer of the EVO family of Implantable Collamer® Lenses (EVO ICL) for myopia, astigmatism and presbyopia, today announced preliminary results for the fourth quarter and fiscal year ended December 29, 2023.","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/718937/000095017024002738/0000950170-24-002738-index.htm","confidence":0.95,"family_label":"Earnings Releases","details":[{"label":"Period","value":"fiscal year ended December 29, 2023"},{"label":"Revenue","value":"Net sales of approximately $322.5 million for fiscal 2023 (preliminary)"},{"label":"Guidance","value":"initiated"},{"label":"Result","value":"preliminary results"}],"fact_type":"earnings_release"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}